$PMCB Announces Launch of New Corporate Website

SILVER SPRING, Md., March 9, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box^(R), today announced that its new website is now live and can be viewed at www.PharmaCyteBiotech.com.

PharmaCyte Biotech’s new website is the latest step in a transformation process to brand PharmaCyte Biotech as solely a biotechnology firm. With the recent name and ticker symbol changes complete, PharmaCyte Biotech continues to implement an aggressive strategy to facilitate the advancement of the treatments it is developing for cancer and diabetes. The new PharmaCyte Biotech website offers a more focused platform to showcase the transformation that has occurred within the company.

Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech, said of the new website, “We have such an incredible story to tell, and this website is going to allow us to bring our journey in leveraging our Cell-in-a-Box^(R) technology, a proprietary live-cell encapsulation platform technology, for the development of ‘targeted’ treatments for solid cancerous tumors and insulin-dependent diabetes to life. We are proud to offer a new website that is easy to navigate, delivers a thorough picture into all that we are doing at PharmaCyte and offers the look and feel expected of a true biotechnology company.”

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box^(R). This unique and patented technology is being used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech’s treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or “cancer-killing” form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This “targeted chemotherapy” has proven remarkably effective in past clinical trials. PharmaCyte Biotech is also working towards improving the quality of life of patients with advanced pancreatic cancer and on developing treatments for other types of solid cancerous tumors. In addition, PharmaCyte Biotech is developing treatments for cancer based upon chemical constituents of the Cannabis plant, known as cannabinoids. In doing so, PharmaCyte Biotech is examining ways to exploit the benefits of Cell-in-a-Box^(R) technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides PharmaCyte Biotech the rare opportunity to develop “green” approaches to fighting deadly diseases, such as cancer of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.

Safe Harbor

This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan” and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte’s ability to continue as a going concern, delays or unsuccessful results in clinical trials or flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.

More information about PharmaCyte Biotech can be found atwww.PharmaCyteBiotech.com. It can also be obtained by contacting Investor Relations.

Investor Relations Contacts:
Jamien Jones
Blueprint Life Science Group
Telephone: 415.375.3340 Ext. 103
jjones@bplifescience.com